293 related articles for article (PubMed ID: 11115082)
1. ACEI/ATRA therapy decreases proteinuria by improving glomerular permselectivity in IgA nephritis.
Woo KT; Lau YK; Wong KS; Chiang GS
Kidney Int; 2000 Dec; 58(6):2485-91. PubMed ID: 11115082
[TBL] [Abstract][Full Text] [Related]
2. Renoprotective effect of small doses of losartan and enalapril in patients with primary glomerulonephritis. Short-term observation.
Tylicki L; Rutkowski P; Renke M; Rutkowski B
Am J Nephrol; 2002; 22(4):356-62. PubMed ID: 12169868
[TBL] [Abstract][Full Text] [Related]
3. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
Campbell R; Sangalli F; Perticucci E; Aros C; Viscarra C; Perna A; Remuzzi A; Bertocchi F; Fagiani L; Remuzzi G; Ruggenenti P
Kidney Int; 2003 Mar; 63(3):1094-103. PubMed ID: 12631093
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-converting enzyme inhibitor versus angiotensin 2 receptor antagonist therapy and the influence of angiotensin-converting enzyme gene polymorphism in IgA nephritis.
Woo KT; Lau YK; Chan CM; Wong KS
Ann Acad Med Singap; 2008 May; 37(5):372-6. PubMed ID: 18536822
[TBL] [Abstract][Full Text] [Related]
5. Disease progression, response to ACEI/ATRA therapy and influence of ACE gene in IgA nephritis.
Woo KT; Lau YK; Zhao Y; Liu FE; Tan HB; Tan EK; Stephanie FC; Chan CM; Wong KS
Cell Mol Immunol; 2007 Jun; 4(3):227-32. PubMed ID: 17601378
[TBL] [Abstract][Full Text] [Related]
6. Proteinuria and angiotensin converting enzyme (ACE) gene polymorphism.
Woo KT; Lau YK
Ann Acad Med Singap; 2000 May; 29(3):383-7. PubMed ID: 10976394
[TBL] [Abstract][Full Text] [Related]
7. Dual renin-angiotensin system blockade plus oral methylprednisone for the treatment of proteinuria in IgA nephropathy.
Trimarchi H; Muryan A; Young P; Forrester M; Iotti A; Pereyra H; Lombi F; Seminario O; Alonso M; Iotti R
Medicina (B Aires); 2007; 67(5):445-50. PubMed ID: 18051227
[TBL] [Abstract][Full Text] [Related]
8. [The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors].
Shi X; Chen X; Liu S; Zhuang Y; Zhang Y
Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):399-403. PubMed ID: 12137603
[TBL] [Abstract][Full Text] [Related]
9. Combined therapy of enalapril and losartan attenuates histologic progression in immunoglobulin A nephropathy.
Tanaka H; Suzuki K; Nakahata T; Tsugawa K; Konno Y; Tsuruga K; Ito E; Waga S
Pediatr Int; 2004 Oct; 46(5):576-9. PubMed ID: 15491387
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of high-dose losartan in IgA nephritis.
Woo KT; Chan CM; Tan HK; Choong HL; Foo M; Vathsala A; Lee EJ; Tan CC; Lee GS; Tan SH; Lim CH; Chiang GS; Fook-Chong S; Wong SK
Clin Nephrol; 2009 Jun; 71(6):617-24. PubMed ID: 19473629
[TBL] [Abstract][Full Text] [Related]
11. Urine protein profile of IgA nephropathy patients may predict the response to ACE-inhibitor therapy.
Rocchetti MT; Centra M; Papale M; Bortone G; Palermo C; Centonze D; Ranieri E; Di Paolo S; Gesualdo L
Proteomics; 2008 Jan; 8(1):206-16. PubMed ID: 18095357
[TBL] [Abstract][Full Text] [Related]
12. Proteinuria: clinical signficance and basis for therapy.
Woo KT; Lau YK
Singapore Med J; 2001 Aug; 42(8):385-9. PubMed ID: 11764058
[TBL] [Abstract][Full Text] [Related]
13. Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy.
Yang Y; Ohta K; Shimizu M; Nakai A; Kasahara Y; Yachie A; Koizumi S
Clin Nephrol; 2005 Jul; 64(1):35-40. PubMed ID: 16047643
[TBL] [Abstract][Full Text] [Related]
14. [Clinical state of a patient with nephrotic proteinuria successfully treated with combined therapy with angiotensin II receptor antagonists and angiotensin II converting enzyme inhibitors and pentoxifylline].
Renke M; Rutkowski P; Tylicki L; Zietkiewicz M; LarczyĆski W; Rutkowski B
Przegl Lek; 2008; 65(6):312-4. PubMed ID: 18853664
[TBL] [Abstract][Full Text] [Related]
15. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
Bazzi C; Rizza V; Paparella M; Casellato D; Napodano P; Olivieri G; D'Amico G
J Nephrol; 2009; 22(3):387-96. PubMed ID: 19557716
[TBL] [Abstract][Full Text] [Related]
16. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
17. Clinical course of patients with IgA nephropathy between combined treatment of immunosuppressive agents and ACE inhibitor and ACE inhibitor alone.
Hwang YC; Lee TW; Kim MJ; Yang MH; Ihm CG
Korean J Intern Med; 2001 Jun; 16(2):105-9. PubMed ID: 11590896
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness of steroid therapy for patients with advanced IgA nephropathy and impaired renal function.
Moriyama T; Honda K; Nitta K; Yumura W; Nihei H
Clin Exp Nephrol; 2004 Sep; 8(3):237-42. PubMed ID: 15480901
[TBL] [Abstract][Full Text] [Related]
19. ATRA therapy restores normal renal function and renal reserve and prevents renal failure.
Woo KT; Lau YK; Chan CM; Wong KS
Ann Acad Med Singap; 2005 Jan; 34(1):52-9. PubMed ID: 15726220
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria.
Tse KC; Li FK; Tang S; Tang CS; Lai KN; Chan TM
Lupus; 2005; 14(12):947-52. PubMed ID: 16425574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]